Elicio Therapeutics Reports Inducement Grants
23 8월 2023 - 5:30AM
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology
company developing a pipeline of novel immunotherapies for the
treatment of cancer, today announced that on August 21, 2023, the
Company’s board of directors approved the grant of 72,980
inducement stock options to two new employees, as an inducement
material to each employee entering into employment with Elicio in
accordance with Nasdaq Listing Rule 5635(c)(4).
Each grant provides for the purchase of shares
of Elicio common stock at a price of $9.99 per share, the closing
price per share of Elicio common stock as reported by Nasdaq on
August 21, 2023, the date of grant.
The grants vest over four years, with 25 percent
of the shares vesting on the first anniversary of each employee’s
respective start date, and the remainder vesting ratably at the end
of each subsequent month thereafter, subject to such employee’s
continued service relationship with Elicio through the applicable
vesting dates.
About Elicio Therapeutics
Elicio Therapeutics is a clinical-stage
biotechnology company developing a pipeline of novel
immunotherapies for the treatment of cancer. By combining expertise
in immunology and immunotherapy, Elicio is engineering
investigational Amphiphile (AMP) immunotherapies intended to
precisely target and fully engage the lymph nodes, the site in our
bodies where the immune response is orchestrated. Elicio is
engineering lymph node-targeted AMPlifiers, immunomodulators,
adjuvants and vaccines for an array of aggressive cancers.
Cautionary Statement Regarding
Forward-Looking StatementsCertain statements contained in
this communication regarding matters that are not historical facts,
are forward-looking statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and the Private
Securities Litigation Reform Act of 1995, known as the PSLRA. These
include statements regarding Elicio’s planned clinical programs and
statements regarding management’s intentions, plans, beliefs,
expectations or forecasts for the future, and therefore, you are
cautioned not to place undue reliance on them. No forward-looking
statement can be guaranteed, and actual results may differ
materially from those projected. Elicio undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise, except to the
extent required by law. We use words such as “anticipates,”
“believes,” “plans,” “expects,” “projects,” “future,” “intends,”
“may,” “will,” “should,” “could,” “estimates,” “predicts,”
“potential,” “continue,” “guidance,” and similar expressions to
identify these forward-looking statements that are intended to be
covered by the safe-harbor provisions of the PSLRA. Such
forward-looking statements are based on our expectations and
involve risks and uncertainties; consequently, actual results may
differ materially from those expressed or implied in the statements
due to a number of factors, including, but not limited to Elicio’s
plans to research, develop and commercialize its current and future
product candidates.
New factors emerge from time to time, and it is
not possible for us to predict all such factors, nor can we assess
the impact of each such factor on the business or the extent to
which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any
forward-looking statements. These risks are more fully discussed in
the current report on Form 8-K that was filed with the SEC on June
2, 2023 and Elicio’s periodic reports and other documents filed
from time to time with the SEC. Forward-looking statements included
in this release are based on information available to Elicio as of
the date of this release. Elicio does not undertake any obligation
to update such forward-looking statements to reflect events or
circumstances after the date of this release, except to the extent
required by law.
Media Contact
Gloria GasaaturaLifeSci
Communicationsggasaatura@lifescicomms.com+1 646-970-4688
Investor Relations Contact
Heather DiVecchiaElicio
TherapeuticsIR@elicio.com+1 857-209-0153
Elicio Therapeutics (NASDAQ:ELTX)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Elicio Therapeutics (NASDAQ:ELTX)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024